News and Announcements
First Graphene (ASX: FGR) Sign MoU with newGen Group
- Published June 29, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- First Graphene Limited and newGen Group sign Memorandum of Understanding to developed mining materials incorporating graphene.
- The agreement will see the addition of graphene into polyurethane liners and ground engaging tools used in mining industry.
- First Graphene believes this new relationship and product development will spark a steady growth in graphene materials used throughout the mining industry.
First Graphene Limited has signed a Memorandum of Understanding (MOU) with newGen Group to develop graphene-enhanced products for the mining services equipment. newGen is a company based in Western Australia who provides liners for leading ore producers. First Graphene has established a graphene production facility in Henderson, Western Australia making the relationship local and easily accessible.
The primary focus of First Graphene’s is to partner with manufacturers in different industries to demonstrate the benefits of graphene has on various applications. The MOU outlines the development of graphene polyurethane liners in mining equipment. The graphene-enhanced liners are expected to bring benefits such as improvements in the operational efficiency and environmental impacts of mining applications. The graphene is set to increase the liners lifespan and produce cost savings in material and labour. First Graphene forecast a more extensive adoption of graphene-enhanced products in the mining field following the development of this new product range.
About First Graphene Limited (ASX: FGR)
First Graphene is an advanced materials company seeking to position itself in the lowest cost quartile of global graphene suppliers. It has developed an environmentally sound and safe method of converting its supplies of ultra-high grade graphite into the lowest cost highest quality graphene, in bulk quantities.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
